Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liu Bao Peng

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|December 30, 2009
[A case of Budd-Chiari syndrome induced by ethinylestradiol and cyproterone acetate]Jing-cheng He, Ping Xu, Liu-bao Peng
Pharmacoeconomics|July 6, 2007
Cost-utility analysis in China: differences and difficulties compared with developed countriesLiu Bao Peng, Chong Qing Tan, Xiao Min Wan, et al.
Cancer|March 17, 2017
Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectivesXiao Min Wan, Liu Bao Peng, Jin An Ma, et al.
BMC Health Services Research|January 18, 2023
Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanomaSi Ni Li, Xiaomin Wan, Liu Bao Peng, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology|December 30, 2009
[A case of Budd-Chiari syndrome induced by ethinylestradiol and cyproterone acetate]Jing-cheng He, Ping Xu, Liu-bao Peng
Pharmacoeconomics|July 6, 2007
Cost-utility analysis in China: differences and difficulties compared with developed countriesLiu Bao Peng, Chong Qing Tan, Xiao Min Wan, et al.
Cancer|March 17, 2017
Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectivesXiao Min Wan, Liu Bao Peng, Jin An Ma, et al.
BMC Health Services Research|January 18, 2023
Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanomaSi Ni Li, Xiaomin Wan, Liu Bao Peng, et al.
Pageof 1